NASDAQ:PETX - Nasdaq -
4.92
-0.01 (-0.2%)
The current stock price of PETX is 4.92 null. In the past month the price increased by 0.61%. In the past year, price increased by 9.82%.
Aratana Therapeutics Inc. is a biopharmaceutical company for animals. The Company is developing compounds for the pet health market, including a non-COXIB analgesic for treating pain, an appetite-stimulating molecule for inappetence and licensed non-opioid local anesthetic for treating post-operative pain. It operates in the United States and Europe. Aratana Therapeutics Inc. is headquartered in Kansas City, Kansas.
Aratana Therapeutics Inc.
11400 TOMAHAWK CREEK PARKWAY SUITE 340
LEAWOOD KS 66211
CEO: Craig A. Tooman
Phone: 913-353-1000
The current stock price of PETX is 4.92 null. The price decreased by -0.2% in the last trading session.
The exchange symbol of Aratana Therapeutics Inc. is PETX and it is listed on the Nasdaq exchange.
PETX stock is listed on the Nasdaq exchange.
Aratana Therapeutics Inc. (PETX) has a market capitalization of 240.93M null. This makes PETX a Micro Cap stock.
Aratana Therapeutics Inc. (PETX) has a support level at 4.62 and a resistance level at 4.95. Check the full technical report for a detailed analysis of PETX support and resistance levels.
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
PETX does not pay a dividend.
Aratana Therapeutics Inc. (PETX) does not have a PE ratio as the earnings reported over the last twelve months were negative (-0.27).
ChartMill assigns a technical rating of 7 / 10 to PETX. When comparing the yearly performance of all stocks, PETX is one of the better performing stocks in the market, outperforming 93.61% of all stocks.
ChartMill assigns a fundamental rating of 5 / 10 to PETX. While PETX has a great health rating, its profitability is only average at the moment.
Over the last trailing twelve months PETX reported a non-GAAP Earnings per Share(EPS) of -0.27. The EPS increased by 68.24% compared to the year before.
Industry Rank | Sector Rank | ||
---|---|---|---|
PM (TTM) | -33.47% | ||
ROA | -12.38% | ||
ROE | -13.47% | ||
Debt/Equity | 0 |
ChartMill assigns a Buy % Consensus number of 60% to PETX. The Buy consensus is the average rating of analysts ratings from 1 analysts.